Synaptogenix Inc (SNPX)

[runncoach]

It's probably true that the industry has given up on it but the reason for the guidelines is due to early stage alzheimer's not having a clear cut pathway to convince the FDA their drugs are better than a placebo, due to difficulty in certainty of the level of dementia in the treatment population. For severe patients there is less variability so cognitive testing can potentially be much more convincing...or at least we all hope so with bryostatin.